Global and multi-region programmes that need one provider with clinical trial,data,technology,and laboratory depth.
Best for: Global,complex programs requiring broad service integration.
Editorial ranking
We compare 239 medical device trials CRO vendors on delivery reliability, compliance readiness, data quality and value - independent profiles compiled from public sources, ranked by evidence. Currently leading: IQVIA, Precision for Medicine, PSI CRO.
Evidence-led comparison
Global and multi-region programmes that need one provider with clinical trial,data,technology,and laboratory depth.
Best for: Global,complex programs requiring broad service integration.
Specialist CRO · Global
Best suited for sponsors seeking clinical cro options in the global coverage lane.. best suited for complex therapies where therapeutic depth and biomarker strategy matter materially.
Best for: Sponsors seeking clinical cro options in the Global coverage lane.
Best suited for sponsors prioritising timeline discipline,mid-market fit,and complex therapeutic depth without defaulting to mega-cro scale.. best suited for sponsors that want global coverage with a more focused and private-CRO operating style.
Best for: Sponsors prioritising timeline discipline,mid-market fit,and complex therapeutic depth without defaulting to mega-CRO scale.
Best suited for programs with heavy regulatory complexity and global filings.. best suited for sponsors that need deep clinical and regulatory support with established global delivery.
Best for: Programs with heavy regulatory complexity and global filings.
Full-service CRO · Global
Best suited for biotech or specialist programs wanting high-touch support and therapeutic alignment with flexible outsourcing structures.. best suited for sponsors who want global capability with more specialist therapeutic posture.
Best for: Biotech or specialist programs wanting high-touch support and therapeutic alignment with flexible outsourcing structures.
Order follows the CVC evidence model. Scores appear only for vendors with verified reviews; a vendor without reviews is never given a number. Read the methodology.
This guide is for medtech manufacturers, start-ups and clinical or regulatory leads choosing a contract research organisation to run a clinical investigation, a performance study or a post-market clinical follow-up programme for a medical device or in vitro diagnostic. If you are looking for the best medical device CRO, the right answer depends on your device class, your target markets and the evidence gap your notified body or regulator has raised. The ranked list above is a starting point for discovery, not a verdict on which vendor will suit your clinical investigation plan; the ranked profiles do not list medical devices among their therapeutic areas, so the table and device profiles below are the more relevant place to start. Vendor scores on Clinical Vendor Compare come only from published platform reviews; a vendor with no reviews shows no score. Use the criteria below to test fit before you shortlist.
A medical device CRO plans and runs clinical investigations under ISO 14155, the good clinical practice standard for devices, rather than ICH E6(R3), which governs medicinal product trials. Typical work spans early feasibility and first-in-human studies, pivotal investigations that support conformity assessment, and post-market studies. Deliverables include the clinical investigation plan (CIP), investigator’s brochure, site training, monitoring, device accountability, safety and device deficiency reporting, data management and the clinical investigation report. Many also support regulatory submissions and clinical evaluation writing.
A regulatory consultancy may write your clinical evaluation report without running any sites. A notified body assesses your technical documentation independently and is not permitted to act as your consultant. A preclinical laboratory handles bench and biocompatibility testing before human use. Drug CROs can run device studies, but their processes are usually built around phases and medicinal products rather than device iterations.
You typically need a device CRO when an equivalence route closes under the EU MDR, when a notified body asks for more clinical data, when your PMCF plan calls for a dedicated study, or when you enter the US under an investigational device exemption (21 CFR Part 812).
Ask how the CRO’s SOPs map to ISO 14155, including risk-based monitoring, CIP content and sponsor oversight duties. Request a redacted monitoring plan and a sample CIP from a comparable device. Be wary of teams that use drug vocabulary throughout; it often signals processes adapted late rather than built for devices.
A capable partner should explain how the investigation feeds your clinical evaluation under Article 61 and Annex XIV of MDR 2017/745, or your performance evaluation under IVDR 2017/746. Ask how they approach equivalence, state of the art, and the link between endpoints, intended purpose and the claims you plan to make.
For a medical device CRO UK sponsors can rely on, check recent MHRA clinical investigation notifications, IRAS submissions and research ethics committee reviews. Ask how the team tracks the GB framework under the UK Medical Devices Regulations 2002, including UKCA marking, the GB post-market surveillance requirements and Northern Ireland’s separate position under the Windsor Framework.
Competent authorities and ethics committees decide whether an investigation may proceed; notified bodies assess the resulting evidence during conformity assessment. Ask who prepares Article 70 applications in each member state, how the CRO handles requests for information, and whether it has supported files that went through the clinical evaluation consultation procedure with expert panels.
Device monitoring covers accountability and traceability by lot or serial number, procedure-day observation, deviations linked to technique, and classification of adverse device effects, serious adverse device effects and device deficiencies. Ask for the safety management plan and how reportable events reach competent authorities under MDR Article 80.
Investigators and site staff need documented training on the device, the CIP and deficiency reporting, often including hands-on or proctored cases. Ask how training is recorded, how roll-in or learning-curve cases are treated in the analysis, and how manufacturer field staff are kept from influencing data during procedures.
Many device endpoints depend on imaging, physiological signals or device logs. Ask whether the EDC meets 21 CFR Part 11 and UK and EU GDPR expectations, how device-generated data is reconciled, and which imaging core labs the CRO has worked with.
Post-market clinical follow-up under Annex XIV Part B is a continuous obligation, not a single study. Ask how the CRO designs PMCF plans and evaluation reports, runs registries or surveys, and feeds findings into the periodic safety update report and summary of safety and clinical performance where these apply. Under the IVDR, the equivalent is post-market performance follow-up.
The table below lists vendors in this category whose profiles mention devices, medtech or diagnostics in their vendor type, service model or therapeutic areas. Use it to narrow a long list by footprint, delivery model and stated focus.
| Vendor | Vendor type | Service model | Geography | Study phases | Therapeutic areas |
|---|---|---|---|---|---|
| Tigermed | Full-service CRO | Full Service CRO | Asia / Global (HQ: China) | Mixed | Oncology, Rare Disease, Medical Devices |
| MedTrials Research | Specialist CRO | Specialist CRO | North America (HQ: USA) | Phase I, Phase II, Phase III | Medical Devices |
| Aixial Group | Specialist CRO | Full Service CRO | Global (HQ: France) | Mixed | Oncology, Cell & Gene Therapy, Medical Devices, Generalist |
| ClinChoice | Full-service CRO | Full Service CRO | Global (HQ: USA) | Mixed | Generalist, Medical Devices & Diagnostics |
| NAMSA | Full-service CRO | Specialist CRO | Global (HQ: USA) | Mixed | Medical Devices |
| Qserve Regulatory & QA | Specialist CRO | Specialist CRO | Europe / Global (HQ: Netherlands) | Phase I, Phase II, Phase III, Phase IV | Medical Devices, Diagnostics |
| AtoZ-CRO | Specialist CRO | Full Service CRO | Europe / USA / India / Global (HQ: Germany) | Phase I, Phase II, Phase III, Phase IV | Generalist, Medical Devices |
| Avania | Specialist CRO | Specialist CRO | Global (HQ: Netherlands) | Mixed | Medical Devices, Diagnostics, Combination Products, Oncology & Radiology, Aesthetics & Dermatology |
| ClinDatrix | Full-service CRO | Specialist CRO | Global (HQ: USA) | Mixed | Medical Devices |
| Veranex | Full-service CRO | Specialist CRO | Global (HQ: USA) | Mixed | Medical Devices |
Every field comes from each vendor’s Clinical Vendor Compare profile. Note that many device-focused vendors record their phases as mixed; device investigations are usually described as feasibility, pivotal or post-market rather than by drug phase, so ask each vendor which stages it covers. Geography ranges from North America to Asia and global coverage, and some generalist CROs list devices alongside other areas. A device listing tells you about stated focus, not ISO 14155 depth, so verify that separately.
Tigermed is recorded as a full-service CRO headquartered in China with Asia and global coverage, mixed phases, and areas spanning oncology, rare disease and medical devices. Its profile describes large Asia and global programmes, with strengths in clinical trial management, regulatory affairs and site management, and its stated fit is sponsors seeking Asia and global coverage. Where to probe: ask for UK and EU device investigations run under ISO 14155 and who owns MDR competent authority submissions.
MedTrials Research is a US-based specialist CRO with North America coverage, Phase I to Phase III listed, and medical devices as its only recorded area. The profile describes focused North American studies for trials needing focused expertise or complex operational handling, citing expert focus, flexibility and domain depth. Where to probe: its profile names very large global programmes needing maximal scale as a limitation, so test European or UK site capacity early.
Aixial Group is recorded as a specialist CRO with a full-service model, headquartered in France with global coverage and mixed phases. Its areas include oncology, cell and gene therapy, medical devices and generalist work at mid-size to large scale. The profile positions it for specialist coverage spanning clinical operations, consulting and FSP support in complex therapy areas. Where to probe: ask how much of its device work runs under ISO 14155.
ClinChoice is listed as a full-service CRO headquartered in the USA with global coverage, mixed phases and a generalist profile that also names medical devices and diagnostics. Its record describes specialist and mid-size global programmes, with strengths in clinical development, post-marketing, functional service support and full-service outsourcing, which may suit sponsors weighing full-service against functional models. Where to probe: ask for PMCF examples and who writes the evaluation reports.
NAMSA is recorded with a full-service CRO type and a specialist service model, headquartered in the USA with global coverage and mixed phases. Medical devices is its only listed area, across specialist and mid-size global programmes. Stated strengths are medical device clinical research and regulatory consulting, which may suit sponsors wanting both from one device-focused provider. Where to probe: ask how independence is kept when regulatory and clinical teams touch the same evidence.
Qserve Regulatory & QA is a specialist CRO headquartered in the Netherlands with Europe and global coverage, listing Phase I to Phase IV and focusing on medical devices and diagnostics. Its profile points to work needing filings, compliance, inspection readiness or QA support, citing regulatory know-how and compliance frameworks. Where to probe: its profile notes it is often best used with clear scope, milestones and document ownership, so agree document owners before contracting.
AtoZ-CRO is recorded as a specialist CRO with a full-service model, headquartered in Germany with coverage across Europe, the USA, India and global markets. It lists Phase I to Phase IV and pairs generalist work with medical devices, citing expert focus, flexibility and domain depth for trials needing complex operational handling. Where to probe: its profile flags very large global programmes needing maximal scale as a limitation, so confirm resourcing for a multi-country pivotal study.
Avania is a specialist CRO headquartered in the Netherlands with global coverage and mixed phases, covering medical devices, diagnostics, combination products, oncology and radiology, and aesthetics and dermatology. The profile positions it for medtech, diagnostics and combination-product sponsors that want a specialist rather than a generalist, citing device-heavy specialisation. Where to probe: for combination products, ask how it reconciles ISO 14155 and ICH E6(R3) obligations in a single plan.
ClinDatrix is recorded with a full-service CRO type and a specialist service model, headquartered in the USA with global coverage and mixed phases. Medical devices is its only listed area, across specialist and mid-size global programmes, and its profile names device clinical trials, regulatory support and data management as its focus. Where to probe: ask how device logs and imaging are reconciled with the EDC, and which UK and EU investigations it has supported.
Veranex is recorded with a full-service CRO type and a specialist service model, headquartered in the USA with global coverage, mixed phases and medical devices as its listed area. Its record describes specialist and mid-size global programmes, with strengths in device clinical research and regulatory consulting, which may suit sponsors wanting clinical and regulatory work from one provider. Where to probe: ask for named investigation leads with UK and EU ISO 14155 experience.
Most sponsors buy device clinical work as a full-service investigation, as functional support for monitoring, data management or safety, or as a hybrid that pairs a specialist device CRO with a separate regulatory consultancy. PMCF registries and surveys are often priced on a unit basis per site or per enrolled participant, while pivotal investigations are quoted as a full budget with pass-through costs.
The main cost drivers are site count and geography, monitoring intensity, procedure-day attendance, device accountability visits, imaging or core lab reads, the number of competent authority and ethics submissions, and regulatory writing such as clinical evaluation reports and PMCF plans. Device design changes mid-study trigger CIP amendments and retraining, so ask how change orders are priced. Integrated regulatory and clinical delivery reduces handovers but concentrates risk with a single vendor; a split model adds coordination cost but keeps an independent eye on the evidence.
Start in the vendor directory, narrow by category and region, and open profiles to check footprint, service model and stated focus. Whether you need a CRO for medtech UK investigations or a global pivotal study, add candidates to compare to view them side by side. When you are ready, use the sponsor RFP to send a structured brief built from the questions above. If you have worked with a device CRO, please write a review; honest accounts of investigations help other sponsors choose well.
Due diligence
Leading vendors in this category combine documented trial experience, therapeutic expertise, robust quality systems, and transparent pricing. Clinical Vendor Compare tracks verified vendor data — experience metrics, review scores, and evidence notes — so sponsors can compare candidates side by side.
Rankings are computed from verified evidence in the CVC vendor dataset: criterion-level scores, platform review scores, public review coverage, and studies managed. No vendor can pay to change a rank; sponsored placements are labelled separately.
The CVC dataset covers hundreds of verified clinical vendors across CRO, technology, and specialist-service categories, each with structured criteria, evidence notes, and source links. Use the compare view on this page to filter by your study needs.
No. Comparison pages, shortlists, and vendor profiles are free for sponsors. Vendors can claim and enhance their profiles, but review data and rankings remain independent.
ISO 14155 is the international good clinical practice standard for clinical investigations of medical devices in human subjects. It covers the clinical investigation plan, ethics, monitoring, safety reporting and the duties of sponsors and investigators. Its requirements align closely with the clinical investigation provisions of the EU MDR, and MHRA guidance points sponsors to it for investigations in Great Britain. A device CRO should run its processes to ISO 14155 rather than adapting drug-trial GCP.
Not necessarily, but the CRO must know the GB process: an IRAS application, research ethics committee review and notification to the MHRA under the UK Medical Devices Regulations 2002 where the device is not UKCA or CE marked for the use being studied. A UK presence helps with site relationships, NHS capacity and local contracting. Ask for recent GB examples and how the team tracks changes in MHRA guidance.
No. Under MDR 2017/745, the sponsor applies to the competent authority of each member state where the investigation will run, alongside ethics committee review. Notified bodies assess the clinical evidence later, as part of conformity assessment of the technical documentation, including the clinical evaluation report and PMCF plan. In Great Britain the MHRA receives the investigation notification, and UK Approved Bodies assess conformity for UKCA marking.
Clinical evaluation is the continuous process, set out in Article 61 and Annex XIV of the EU MDR, of collecting and appraising clinical data to show that a device is safe and performs as intended. A clinical investigation is one source of that data: a study in human subjects run under ISO 14155. Literature, equivalence data and post-market experience can also contribute, but higher-risk devices often need their own investigation.
Post-market clinical follow-up is the proactive collection of clinical data on a CE-marked device in routine use, described in Annex XIV Part B of the EU MDR. It can include registries, surveys, literature review and dedicated PMCF investigations. Many device CROs run PMCF studies and help draft the plan and evaluation report, but the manufacturer remains responsible for keeping the clinical evaluation up to date.
Under IVDR 2017/746, diagnostics are supported by performance evaluation, which combines scientific validity, analytical performance and clinical performance. Clinical performance studies take the place of clinical investigations, and post-market performance follow-up takes the place of PMCF. Studies using leftover samples follow different rules from interventional studies that affect patient management, so choose a CRO with specific IVD experience in sample logistics and reference methods.
Look for a CRO for medtech UK studies that is comfortable with small, iterative investigations, device accountability, procedure-day support and investigator training on technique, and that understands UKCA, CE marking and the MDR evidence bar. Ask how the team scales from an early feasibility study to a pivotal investigation, whether it can support PMCF afterwards, and how it manages design changes without losing data integrity.
Usually not for a device-only investigation, which follows ISO 14155. ICH E6(R3) governs trials of medicinal products. Combination products and studies where a device delivers a medicine may need to satisfy both, depending on which component drives the regulatory route. Agree early with your CRO which standard governs each process, and document how monitoring, safety reporting and the trial master file reconcile the two.